click enter text
updat estim iclr lh
updat estim note updat estim price target
ep bridg iclr lh well summar key
takeaway recent earn report confer call
solidli increas ep guid
say see low-end rang less like beat
influenc sg time upsid brazil also
primarili driven time explain guid increas wasnt larger
est increas price target increas
iclr modestli increas revenue guid ep guid
net book-to-bil basi revenu
signific y/i tailwind compani character
line expect ep est increas
consist iclr ep revis price target increas
modestli full year guidanc reiter rais guidanc
guidanc gener line wr consensu
end becam awar larg trial cancel remov
backlog pass through servic revenu base
ttm net book-to-bil estim net book-to-bil
compani emphas strong busi momentum
confer call estim price target unchang
lh solidli increas ep guidanc
organ revenue growth diagnost segment above-
expect analysi suggest upsid revenue guidanc possibl
estim increas modestli reflect annual
envigo revenue synergi partial off-set higher interest expens lower
share repurchas price target increas
ep beat revenue miss guidanc midpoint compani cite
lower-than-expect pass payment full year guidanc
reiter gross book rel flat cancel also
typic level data revenue declin y/i provid
guidanc est unchang ep
moder slightli lower growth clinic data price target
decreas lower estim modestli lower
multipl given low visibl clinic revenu ramp data trajectori
laboratori corp
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
takeaway quarter
link first take note
report fiscal adjust ep wolfe/consensu ep
compani said expect ep rel flat y/i fiscal
cite benefit expens shift fiscal
adjust oper y/i estim
pharma distribut outperform estim
increas ep guidanc rais come lower share count
vs previous less beat even take account although note
confid would low end revis rang
also note upsid brazil primarili relat time stock comp health benefit
accrual balanc rest year underli oper perform line
expect separ benefit note
record impair charg relat pharmedium compani believ difficult
volum return previou level expect enter consent decre allow product
nj tx facil continu consent decre would also expect specifi requir
tn facil largest open compani close smallest least autom facil ms
pharmedium result expect headwind abc growth fiscal pharmedium lose
fiscal small profit fiscal significantli profit fiscal
pharma distribut oper incom grew exclud pharmedium brazil
continu believ distributor would parti best posit support transit pos
rebat contract administr chargeback
ep estim increas consist abc guidanc revis
year-end price target increas continu base ebit
estim target ev ebit multipl
exhibit summari estim chang
page
exhibit ep bridg
page
takeaway quarter
link first take note
iclr report ep wolfe/consensu ep primarili driven
modest revenu upsid margin gener line
revenu y/i constant currenc fx wolfe/consensu
revenu
oper incom y/i modestli estim
oper margin increas y/i estimate
compani rais midpoint revenu guidanc ep
guidanc
net book-to-bil basi compar histor data
cancel basi associ pass payment
includ uptick underli cancel rate
revenu custom segment
top custom revenu signific y/i tailwind compani character
line expect see tabl custom segment data
exhibit iclr revenu growth custom segment
ep estim increas consist iclr guidanc revis
year-end price target increas base ebit estim
target ev ebit multipl vs previous
page
exhibit summari estim chang
exhibit ep bridg
page
takeaway quarter
link first take note
guidanc gener line estim consensu revenu ebitda
report adjust ep modestli guidance/wolfe/consensu ep
reiter guidanc across metric rais guidanc
ep
end becam awar larg trial cancel remov backlog
backlog q/q q/q ex cancel vs q/q q/q
base ttm net book-to-bil estim net book-to-bil
compani emphas strong busi momentum confer call provid rel littl
estim year-end price target unchang
exhibit summari estim chang
exhibit ep bridg
page
laboratori corp america hold lh
takeaway quarter
link first take note
lh report adjust ep wolfe/consensu ep driven better
expect result covanc diagnost
recal lh expect ep similar report
lh increas ep guidanc
revenu y/i organ busi disposit fx
diagnost volum growth organ acquir
lh size benefit weather headwind calendar headwind
net impact manag network chang leav core volum growth
volum headwind network chang consist month
quarter contrast dgx comment around acceler benefit
headwind smaller compani previous expect
see diagnost revenu guidanc fairli conserv
oper incom y/i estim
oper margin declin y/i estim
given magnitud revenu out-performance surpris upsid
vs oper incom estim
revenu y/i fx acquisit organ
estim
importantli organ growth reduc lower y/i pass payment exclud pass
through organ revenu growth line guidanc
oper incom y/i estim
oper margin improv y/i note come lower pass-
payment associ oper incom
envigo deal hand smaller acquisit mi bioresearch mng diagnost rcri
includ revenu guidanc covanc unchang vs initi guidanc provid
result lh suggest benefit unannounc acquisit alreadi
includ initi guidanc clear us head quarter
manag note envigo busi margin segment averag consist
expect synergi expect next two year
page
lh report organ revenu growth shown tabl
adjust impact favor weather unfavor calendar core organ revenu growth
also
analysi hold core organ revenu growth constant balanc
use known item bridg back organ revenu growth report
notic analysi fulli reflect headwind lh expect divestitur
headwind expect foreign exchang rate
note lh calendar expect differ modest headwind expect
lh see differ compani assumpt primarili driven geograph mix
analysi would suggest full year report revenu growth compar guidanc
suggest us guidanc imb conservat around sustain
core organ growth conservat imbed impact manag
page
report calcul full year simpl report plug arriv full year guidanc report plug arriv full year guidanc reportedorgan report calcul full year simpl averageweath report none assum rest year despit potenti easi comp littl less slight headwind complet revers enu calcul base comment calcul full year simpl averageestim
ep estim unchang slightli midpoint lh revis full year
guidanc
ep estim increas modestli reflect annual envigo revenu
synergi partial off-set higher interest expens lower share repurchas
estim consensu estim slightli driven belief
pama larger headwind contempl consensu estim
year-end price target increas continu base ep
estim target price-to-earnings multipl
exhibit summari estim chang
exhibit ep bridg
page
takeaway quarter
link first take note
report adjust ep guide/wolfe/consensu ep
guidanc reiter across metric
revenu y/i constant currenc fx guide/wolfe/consensu
revenue
constant currenc growth midpoint guid driven lower pass through
data revenu y/i estim provid guidanc
net book-to-bil modestli figur report
gross book increas y/i q/q
cancel begin backlog continu favor trend seen
net award increas y/i declin slightli q/q
new award come pharma biotech
manag see cro environ stabl steadi rfp flow
note client take longer determin final trial design lead slower start time
also note client awar potenti disrupt regulatori chang medicare-for-al
appear chang develop program
regard rel flattish gross book ceo colin shannon cite stronger competit
believ enough busi go around
estim unchang estim moder slightli lower growth
clinic research data
year-end price target decreas base ebit estim
target ev ebit multipl vs previous account lower visibl ramp
clinic revenu growth balanc year overhang uncertain data trajectori
miss revenu guidanc even reason explan hardli ideal year
signific revenu guidanc ramp built guidanc
page
exhibit summari estim chang
exhibit ep bridg
page
